DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: albuterol sulfate; ipratropium bromide

Summary for Generic Name: albuterol sulfate; ipratropium bromide

Tradenames:4
Patents:23
Applicants:9
NDAs:10
Drug Master File Entries: see list33
Suppliers: see list6
Formulation / Manufacturing:see details

Pharmacology for Ingredient: albuterol sulfate; ipratropium bromide

Clinical Trials for: albuterol sulfate; ipratropium bromide

Budesonide Inhalation Suspension for Acute Asthma in Children
Status: Completed Condition: Asthma; Acute Asthma; Reactive Airway Exacerbation

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Status: Recruiting Condition: Respiratory Disease in Familial Dysautonomia

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
Status: Completed Condition: COPD

An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

A Crossover Study in the Treatment of Patients With COPD
Status: Completed Condition: Chronic Obstructive Pulmonary Disease

Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease
Status: Terminated Condition: Chronic Obstructive Pulmonary Disease

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation
Status: Completed Condition: Asthma

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Nebulized Bronchodilatators and Cardiac Repolarization
Status: Recruiting Condition: Influence of Nebulized Bronchodilatators on Selected; Electrophysiological Parameters

A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)
Status: Completed Condition: Asthma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
COMBIVENT
albuterol sulfate; ipratropium bromide
AEROSOL, METERED;INHALATION020291Oct 24, 1996RXYes5,603,918<disabled>
Apotex Inc
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION077117Dec 31, 2007DISCNNo<disabled>
Cipla Ltd
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION077559Dec 31, 2007RXNo<disabled>
Nephron
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION076749Dec 31, 2007RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc